Melissa officinalis is a medicinal plant rich in biologically active compounds which is used worldwide for its therapeutic effects. Chemical studies on its composition have shown that it contains mainly flavonoids, terpenoids, phenolic acids, tannins, and essential oil. The main active constituents of Melissa officinalis are volatile compounds (geranial, neral, citronellal and geraniol), triterpenes (ursolic acid and oleanolic acid), phenolic acids (rosmarinic acid, caffeic acid and chlorogenic acid), and flavonoids (quercetin, rhamnocitrin, and luteolin).
Component Name | Content *, μg/g |
Part of Plant | Reference | |
---|---|---|---|---|
Part of Plant | Reference | |||
Betulinic acid | 12.85–169.88 | aerial parts | [4] | |
Phenolic acids | Caffeic acid | 39.38–860.72 | Dried leaves | [4] |
[ | 12 | ][13][14][15][16] | [12,13,14,15,16] | |
Citronellal | 0.4–20.3 | [12][13][15][16][17] | [12,13,15,16,17] | |
Geranial (citral A) | 6.22–51.21 | [14][15][16][17][ |
Effect | Model | Dosage or Concentration | Tested Systems | Results | Type of Extract | Reference |
---|
Antiproliferative | in vitro | 20, 100, 250 μg/mL | Breast cancer cells MDA-MB- 231 and healthy HaCat cells |
Inhibitory effect on migration and proliferation of both types of cells | ethanolic extract | [34] | [38] | |||||||||
Oleanolic acid | 915.03–6151.67 | aerial parts | [4] | |||||||||||||
Caftaric acid | 1.85–344.34 | Dried leaves | ||||||||||||||
in vitro | 50% | Human Colon Cancer Cell Line (HCT-116) | [4] | The 50 % ethanolic extract showed significant differences after 72 h of treatment, reducing cell proliferation to values close to 40% | ethanolic and aqueous extracts | [35] | [39] | Ursolic acid | 3577.00–11,234.97 | aerial parts | ||||||
Antitumor | in vitro | Different concentration | [4] | |||||||||||||
Human tumor cell lines: MCF-7, | AGS and NCI-H460 | Obtained revealed that the ethanolic extract presented the highest cell growth inhibitory potential in all the human tumor cell lines tested | ethanolic, methanolic, hydro-methanolic, | 23-Sulfate ester of niga-ichigoside F1 | n.a. | leaves and stems | [24] | [25] | 18 | |||||||
3β,16β,23-Trihydroxy-13,28-epoxyurs-11-ene-3-O-β-D-glucopyranoside | n.a. | dried leaves and stems | [23] | [24] | ||||||||||||
3,23-Disulfate ester of 2α,3β,19α,23-tetrahydroxyurs-12-en-28-oicacid | n.a. | dried leaves and stems | [23] | [24] | ||||||||||||
Chlorogenic acid | 0.62–75.529 | Dried leaves | [4][28] | [4,29] | ||||||||||||
hydro-ethanolic and aqueous extracts) | [ | 36 | ] | [ | 40 | ] | Ferulic acid | 1.03–45.489 | Dried leaves | [4][28] | [4,29] | |||||
Antioxidant | in vitro | Different concentration | Encephalic tissue from male Wistar rats | Effective agent in the prevention of various neurological diseases associated with oxidative stress | ethanolic, methanolic and aqueous extracts | [37] | [41 | ] | [14 | Gentisic acid | ,15, | 10.40–60.48 | 16,17,18] | |||
Dried leaves | [ | 4 | ] | |||||||||||||
] | ||||||||||||||||
in vitro | 1, 2.5, 5 and 10 mg/mL | DPPH radical scavenging activity assay, β-carotene bleaching test and ABTS assay | Good antioxidant activity | essential oil | [38] | Geranyl acetate | 0.5–19.3 | [12][13][14][17] | [12,13,14,17] | |||||||
[ | 42 | ] | p-Coumaric acid | 1.06–20.72 | Dried leaves | [4] | ||||||||||
Antiangiogenic | in vitro, in ovo | 50 μg/mL | Two breast cancer cell lines, MCF-7 And MDA-MB-231 |
Highest cell inhibitory activity was exhibited by the 96% ethanolic extract | ethanolic extracts and methanolic extracts | [4] | Neral (citral B) | 3,23-Disulfate ester of 2α,3β,19α,23-tetrahydroxyurs-12-en-28-oicacid 28-O-β-D-glucopyranoside4.28–35.02 | [12][13 | n.a. | ][14 | dried leaves and stems | [23] | [24] | ||
Cardioprotective | ||||||||||||||||
13.37 ± 2.84 | Aerialparts | in vivo | [29] | [30 | ][15][16][17][18] | [12,13,14,15,16,17,18] | ||||||||||
] | 25, 50 and 100 mg/kg b.w. * | (4.23/8.46/16.91 mg/kg b.w. *) | Rats | Antioxidant and cardio-protective effects against arrhythmias induced by ischemia and ischemia-reperfusion | ethanolic leaf extract | [39] | [43] | α-Cadinol | 5.64 | [14] | ||||||
3,23-Disulfate ester of2α,3β,23,29-tetrahydroxyolean-12-en-28-oicacid | n.a. | dried leaves and stems | [23] | [24] | ||||||||||||
Rosmarinic acid | 3515.60–86,637.60 | Dried leaves | [4] | |||||||||||||
Antinociceptive Antihyperglycemic |
in vivo | 0.01, 0.02 and 0.04 mg/day | (0.0063/0.0126/0.0252 mg/kg b.w. *) | Male adult Wistar rats | Long-term oral administration of essential oil (at an effective dose of 0.04 mg/day) can suppress chemical hyperalgesia in diabetic rats | essential oil | [40] | [44] | α-Copaene | 0.1–7.02 | [12 | 3,23-disulfate ester of 3β-23,29-trihydroxyolean-12-en-28-oic acid | ][15][16 | n.a. | dried leaves and stems | [ |
6914.1 ± 779 | Aerial parts | [29] | ] | [12,15 | [30 | 23] | [24] | |||||||||
Anxiolytic Antidepressant | , | 16] | ||||||||||||||
in vivo | 50, 75 and 150 mg/kg b.w./day * | (3.91/5.86/11.72 mg/kg b.w. *) | Albino BALB/c male mice | Hydro-alcoholic extract (75 and 150 mg/kg) significantly reversed anxiety- and depressive-like behaviors | hydro-alcoholic extract | [41] | [45] | β-Caryophyllene | 1.3–29.14 | [14][15][16][17] | 3,23-Disulfate ester of 2α,3β-23,29-tetrahydroxyolean-12-ene-28-oicacid | [14, | n.a. | 15,16 | dried leaves and stems | |
Neuroprotective | in vitro | ,17] | ||||||||||||||
5, 10, 50, 100, 500 μg/mL | [ | 23 | ] | [24] | ||||||||||||
] | ||||||||||||||||
Flavonoids | Apigenin | 0.66–84.53 | Dried leaves | Cortical neuronal Culture system | [4][28] | [4,29] | Protective effects on neurons in the brain |
balm oil | [ | Minority components (<5%) | ||||||
42 | 23-sulfate ester of 2α,3β,19 α,23-tetrahydroxyurs-12-en-28-oic acid | n.a. | fresh leaves and stems | [25] | [26] | |||||||||||
] | [ | 46 | (2E)-Nonen-1-al | 23-sulfate ester of 2α,3β,19 α,23-tetrahydroxyurs-12-en-28-oic acid 28-O-β- 0.2 |
D-glucopyranoside | n.a.[12 | fresh leaves and stems | [25] | [26] | |||||||
] | ] | |||||||||||||||
(E)-Nerolidol | 0.2 | Melissioside A[12] | ||||||||||||||
n.a. | leaves and stems | [ | 24] | [25] | (E)-α-Bergamotene | 1.24 | [14] | |||||||||
Melissioside B | n.a. | leaves and stems | [24] | [25] | ||||||||||||
Melissioside C | n.a. | leaves and stems | [24] | [25] |
Group Name | Compound Name | Content *, μg/g |
||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
41.71 ± 20.6 | ||||||||||||||||||
Aerial parts | ||||||||||||||||||
[ | ||||||||||||||||||
29 | ||||||||||||||||||
] | ||||||||||||||||||
[ | ||||||||||||||||||
30 | ||||||||||||||||||
] | ||||||||||||||||||
Cynaroside | 408.13 ± 30.0 | |||||||||||||||||
in vivo | 50, 100, 200 and 400 mg/kg b.w. * | (8.35/16.71/33.41/66.83 mg/kg | b.w. *) | Male rats | Treatment with 100 mg/kg of oil attenuated the increased caspase-3 like protease activity significantly |
balm oil | [42] | [46] | Aerial parts | [29] | [30] | |||||||
(E)-β-Ionone | 0.9 | |||||||||||||||||
GABA-T inhibitor | in vitro | 0–4 mg/mL | Rat brain | Phytochemical characterization of the crude extract determined rosmarinic acid as the major compound responsible for activity (40% inhibition at 100 μg/mL) since it represented approximately 1.5% of the dry mass of the leaves | methanol extract | [12] | ||||||||||||
[ | 43 | ] | [ | 47 | ] | Daidzein | 51.25 ± 8.07 | Aerial parts | [29] | [30] | ||||||||
Anti-kinetoplastidae | in vitro | 31.25, 62.5, 125, 250 μg/mL | T. cruzi | , | L. brasiliensi | , | L. infantum | A potential source of natural product featuring anti- | Leishmania | and anti- | Trypanosoma | activity | ethanol extract | [44] | [48] | Hyperoside | 3.30–16.240 | (E)-β-Ocimene |
Analgesic | Dried leaves | in vivo | 5, 10, 20 mg/kg b.w. * | (0.87/1.73/3.46 mg/kg | b.w. *) | [4] | 0.1–0.5 | |||||||||||
Male Wistar rats | Intrathecal administration could significantly improve hot-water and formalin-induced pain in male Wistar rats | hydro-alcoholic extract | [ | 45 | ] | [49] | Isoquercetin | 6.82–162.40 | Dried leaves | [4] | ||||||||
Hypnotic | in vivo | 200, 400 and 800 mg/kg b.w. * | (14.81/29.61/59.23 mg/kg | b.w. *) | Male Swiss mice | Extracts may be useful for insomnia | hydro-alcoholic extracts | [46] | [50] | [12][13 | Kaempherol | ] | [12 | 21.84 | ,13] | |||
Dried leaves | [ | 4 | ] | |||||||||||||||
Antidiabetic | in vivo | 0.0125 mg/d | db/db mice | Anti-hyperglycaemic agent | essential oil | [47] | [51] | (E-E)-Geranyl linalool | 1.59 | Luteolin | 0.81–26.32 | Dried leaves | [4] | |||||
in vivo | 0.4%, 0.8% ( | w | / | w | ) | [14] | ||||||||||||
Otsuka Long-Evans Tokushima fatty rats | An effective therapeutic strategy to treat human obesity and type 2 diabetes | herbal extract | [ | 48 | ] | [52] | (Z)-β-Ocimene | 0.1 | Myricetin | [15] | ||||||||
3.45–17.92 | Dried leaves | [ | 4] | |||||||||||||||
Anti-Alzheimer | in vitro | 8.8 mg/mL | GSK-3Β, CK-1δ, and BACE-1 | Best activity for ck-1δ inhibitory activity with maximum inhibitory concentration values at half (IC50) below 250 μg/mL | methanol extract | [49] | [53] | 1,2-Benzenedicarboxilic acid, butyl 2-methylopropyl ester | 0.6 | [ | Quercetin | 13] | ||||||
153.46 | Dried leaves | [ | 28] | [29] | 1,8-Dehydro-cineol | 0.1 | [13] | |||||||||||
14-Hydroxy-9-epi-(E)-caryophyllene | 0.2 | [13] | ||||||||||||||||
1-Octen-3-ol | 0.2–0.3 | [12][13][15] | [12,13,15] | |||||||||||||||
3,5-Heptadienal,2-ethylidene-6-methyl | 0.4 | [13] | ||||||||||||||||
3-Octanone | 0.2 | [17] | ||||||||||||||||
6-Methyl-5-hepten-2-ol | 0.2–1.7 | [12][13][15] | [12,13,15] | |||||||||||||||
Benzene acetaldehyde | 0.3 | [12] | ||||||||||||||||
Camphene | 0.38–1.38 | [14][16] | [14,16] | |||||||||||||||
Camphor | 0.1–0.4 | [13][15] | [13,15] | |||||||||||||||
Carvacrol | 0.3–1 | [12][13] | [12,13] | |||||||||||||||
Caryophyllenol | 0.5–2.23 | [14] | ||||||||||||||||
cis-2H-3a-Methyl-octahydro-Inden-2-one | 4.7 | [17] | ||||||||||||||||
Cis-Chrysanthenol | 0.7–1.7 | [12][13][15] | [12,13,15] | |||||||||||||||
Cis-Rose oxide | 0.1–0.2 | [12][15] | [12,15] | |||||||||||||||
Citronellol | 0.4–1.88 | [12][14] | [12,14] | |||||||||||||||
Citronellyl acetate | 0.1 | [12] | ||||||||||||||||
Dihydrocitronellol acetate | 0.3 | [15] | ||||||||||||||||
Geraniol | 0.6–0.7 | [12][13][15] | [12,13,15] | |||||||||||||||
Germacrene D | 0.2–2.0 | [12][13][14] | [12,13,14] | |||||||||||||||
Humulene epoxide II | 0.2–1.29 | [13][14] | [13,14] | |||||||||||||||
iso Aromadendren epoxide | 0.46 | [14] | ||||||||||||||||
Isogeranial | 1.4–2.0 | [13] | ||||||||||||||||
Isomenthol | 2.4 | [15] | ||||||||||||||||
Linalool | 0.3–0.5 | [12 | ||||||||||||||||
Antispasmodic | ex vivo | 1, 5, 10, 25, and 50 mg/mL | Different segments of the gastrointestinal tract of mice | Site- and dose-dependent effects on the contractile activity of the gastrointestinal tract | hydro-ethanolic leaf extract | [50] | [54] | Quercetrol | 5.72–33.60 | Dried leaves | ][15] | [12,15] | ||||||
[ | 4 | |||||||||||||||||
Antiviral | ] | Linalool + trans-Sabinene hydrate | 0.5–0.8 | [13] | ||||||||||||||
Menthol | ||||||||||||||||||
in vitro | 1.5–150 μg/mL | RC-37 cells | High virucidal activity against | 0.3 | [15] | |||||||||||||
Methyl citronellate | 0.5–2.78 | [12][13][16] | [12,13,16] | |||||||||||||||
Methyl eugenol | 0.1 | [12] | ||||||||||||||||
Methyl geranate | 0.2–0.4 | [12][13][17] | [12,13,17] | |||||||||||||||
Myrcene | 0.1–0.3 | [13][15] | [13,15] | |||||||||||||||
n-Eicosane | 0.6 | [15] | ||||||||||||||||
Nerol | 0.2 | [15] | ||||||||||||||||
Neryl acetate | 0.1 | [12] | ||||||||||||||||
n-Heneicosane | 0.4 | [15] | ||||||||||||||||
n-Nonanal | 0.1–0.4 | [12][15] | [12,15] | |||||||||||||||
para-Mentha-1(7),8-diene | 0.1 | [13] | ||||||||||||||||
p-Cymene | 0.1 | [12][13] | [12,13] | |||||||||||||||
Phytol | 3.64 | [14] | ||||||||||||||||
Rosefuran epoxide | 0.6–0.7 | [13] | ||||||||||||||||
Sabinene | 0.4 | [13] | ||||||||||||||||
Thymol | 0.1–3.1 | [12][13][14] | [12,13,14] | |||||||||||||||
t-Muurolol | 0.59 | [14] | ||||||||||||||||
trans-Limonene oxide | 0.6 | [13] | ||||||||||||||||
trans-para-Mentha-1(7),8-dien-2-ol | 2.3 | [17] | ||||||||||||||||
HSV-1 | aqueous extract | [ | 51 | ] | [ | 55] | Rutin | 8.11–1462.99 | Dried leaves | Trans-Rose oxide | ||||||||
Antifungal | in vitro | [ | 4] | [4 | [28] | ,29] | 0.1 |
15.5–2000 μg/mL |
Human | |||||||||||
Pathogenic fungi | |||||||||||
Good antifungal activity | |||||||||||
ethanol extracts | |||||||||||
[ | |||||||||||
52 | |||||||||||
] | |||||||||||
[ | |||||||||||
56 | |||||||||||
] | |||||||||||
[ | |||||||||||
12 | |||||||||||
] | |||||||||||
[ | |||||||||||
15 | |||||||||||
] | |||||||||||
[ | |||||||||||
12 | |||||||||||
0.25–2 μL/mL | Phytopathogenic fungi in apples | essential oil | [53] | [57] | |||||||
Antibacterial | in vitro | 10 and 15 mg/mL | E. coli | , | L. monocytogenes | , | S. aureus | and | S. typhimurium | A significant antimicrobial effect | essential oil |
, | |||||||||||
15 | |||||||||||
] | |||||||||||
[ | 38 | ] | [ | 42 | ] | ||||||
Valencene | |||||||||||
0.1 | |||||||||||
[ | |||||||||||
15 | |||||||||||
] | |||||||||||
α-Humulene | |||||||||||
0.2–2.6 | |||||||||||
[ | |||||||||||
12 | |||||||||||
] | |||||||||||
[ | |||||||||||
13 | |||||||||||
] | |||||||||||
[ | |||||||||||
15 | |||||||||||
] | |||||||||||
[ | |||||||||||
16 | |||||||||||
] | |||||||||||
[ | |||||||||||
12 | |||||||||||
, | |||||||||||
13 | |||||||||||
, | |||||||||||
15 | |||||||||||
, | |||||||||||
16 | |||||||||||
] | |||||||||||
α-Calacorene | 0.76 | [14] | |||||||||
α-Cubebene | 0.42–1.23 | [14] | |||||||||
β-Cubebene | 0.1 | [15] | |||||||||
β-Pinene oxide | 1.1 | [13] | |||||||||
β-sesquiphellandrene | 0.97 | [14] | |||||||||
γ-Cadinene | 0.76–1.77 | [14] | |||||||||
γ-Terpinene | 0.3–0.5 | [12][13] | [12,13] |